Piper Sandler raised the firm’s price target on Amgen (AMGN) to $381 from $342 and keeps an Overweight rating on the shares. The firm notes monthly third-party prescription data for October 2025 became available recently, and this piece highlights Rx data and trends for a number of key Amgen products. Looking at Repatha and Tezspire more specifically, Piper continues to believe that visibility into aggressive volume growth for both products is high.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN: